VALERIAN MONOGRAPH STATUS AS OTC NIGHTTIME SLEEP AID IS SOUGHT
This article was originally published in The Tan Sheet
Executive Summary
VALERIAN MONOGRAPH STATUS AS OTC NIGHTTIME SLEEP AID IS SOUGHT, based largely on the ingredient's marketing history in Europe, by the European-American Phytomedicines Coalition in a June 8 citizen petition to FDA. "Adequate data are available to establish that valerian is not a new drug," EAPC maintained, "because it is generally recognized as safe and effective and has been marketed for a material time and to a material extent."
You may also be interested in...
Additional Valerian Safety Data Needed To Gain OTC Status, FDA Says
Additional data on valerian's safety must be provided to FDA before the agency can consider including the botanical in the final monograph for OTC nighttime sleep aid drugs, FDA states in an April 7 letter to European-American Phytomedicines Coalition (EAPC) counsel Robert Pinco
Additional Valerian Safety Data Needed To Gain OTC Status, FDA Says
Additional data on valerian's safety must be provided to FDA before the agency can consider including the botanical in the final monograph for OTC nighttime sleep aid drugs, FDA states in an April 7 letter to European-American Phytomedicines Coalition (EAPC) counsel Robert Pinco
Additional Valerian Safety Data Needed To Gain OTC Status, FDA Says
Additional data on valerian's safety must be provided to FDA before the agency can consider including the botanical in the final monograph for OTC nighttime sleep aid drugs, FDA states in an April 7 letter to European-American Phytomedicines Coalition (EAPC) counsel Robert Pinco